-

Komodo Health Recognized by Forbes, TIME, and The Healthcare Technology Report for Healthcare Analytics AI Innovation

Triple recognition validates company’s pioneering healthcare-native AI approach and accelerated market leadership

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Komodo Health, the leader in AI-powered healthcare intelligence, today announced that it has earned recognition on three prestigious industry lists: the 2025 Forbes Cloud 100, TIME’s inaugural World’s Top HealthTech Companies, and The Healthcare Technology Report’s Top 25 Healthcare Software Companies. These honors validate Komodo’s differentiated approach to healthcare analytics AI — purpose-built from the ground up rather than retrofitted from consumer applications — and arrive during a milestone year of unprecedented growth and innovation.

“These recognitions reflect our team’s dedication to building healthcare analytics AI the right way," said Web Sun, President and Co-Founder, Komodo Health.

Share

Breakthrough AI Innovation Drives Market Leadership

The recognition comes as Komodo accelerates its market leadership through breakthrough AI innovation. The company recently launched Marmot™, the industry's first healthcare-native AI engine, which fundamentally transforms how organizations generate insights from healthcare data. Unlike foundational AI models adapted for healthcare use, Marmot was engineered specifically for healthcare and Life Sciences workflows with deep domain expertise, advanced analytics, and healthcare-specific reasoning capabilities.

Built on Komodo's Healthcare Map®, which captures insights from over 330 million de-identified U.S. patients, Marmot delivers transparent, verifiable insights in minutes rather than weeks, enabling critical decisions across the entire product life cycle, from clinical trial design to post-market evidence generation.

Expanding Impact Across Healthcare and Beyond

Komodo’s influence extends well beyond traditional healthcare boundaries. The company powered more than 250 peer-reviewed studies and 31 presentations at ISPOR 2025, demonstrating the scientific rigor and real-world impact of its healthcare analytics AI platform. Additionally, Komodo is advancing healthcare insights for Financial Services through a groundbreaking partnership with Nasdaq while broadening strategic alliances with leading technology innovators, including Databricks and Snowflake.

“These recognitions reflect our team’s dedication to building healthcare analytics AI the right way — leveraging decades of domain expertise and 11 years of executing on our full stack thesis, spanning our Healthcare Map, platform capabilities, and healthcare analytics AI,” said Web Sun, President and Co-Founder, Komodo Health. “Marmot validates our core thesis: When AI is purpose-built for healthcare workflows rather than retrofitted from consumer applications, teams get the speed and transparency they need to drive their business and improve patient outcomes with confidence.”

Industry Validation for Purpose-Built AI

The Forbes Cloud 100, which Komodo has been recognized on five times, represents the definitive ranking of the top 100 private cloud companies globally. TIME’s World’s Top HealthTech Companies highlights companies that deliver the most impactful health technologies. Komodo earned specific recognition in the AI & Data Analytics category with an “Outstanding” performance indicator. The Healthcare Technology Report honors healthcare software companies that are defining the future of healthcare delivery through advanced analytics and AI-driven solutions.

Together, these recognitions underscore Komodo's market-defining approach, as the healthcare industry increasingly demands solutions that balance rapid insights with strict regulatory compliance. Marmot’s healthcare-native design uniquely delivers the analytical rigor and transparency that critical decisions require and positions Komodo to set the industry standard for trustworthy, high-impact insights.

About Komodo Health

Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company's healthcare-native AI engine Marmot, powered by the Healthcare Map, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle. For more information, visit www.komodohealth.com.

Contacts

Rowena Kelley
858.405.1971
media@komodohealth.com

Real Chemistry for Komodo Health
KomodoHealthTeam@realchemistry.com

Komodo Health


Release Versions

Contacts

Rowena Kelley
858.405.1971
media@komodohealth.com

Real Chemistry for Komodo Health
KomodoHealthTeam@realchemistry.com

Social Media Profiles
More News From Komodo Health

Komodo Health Appoints Mark Jewett to Chief Marketing Officer

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Komodo Health, the leader in AI-powered healthcare intelligence, today announced the appointment of Mark Jewett as Chief Marketing Officer (CMO). Jewett will lead the company’s marketing, shaping brand, communications, and go-to-market strategy as it scales Marmot™ — its new AI platform designed to help Life Sciences and healthcare organizations innovate faster and serve patients better. The appointment comes following a period of significant momentum...

Komodo Health Analysis Uncovers Dual Reality in Metastatic Breast Cancer Care: Rapid Targeted Cancer Therapy Adoption Amid Glaring Age-Related Disparities

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--On the 40th anniversary of Breast Cancer Awareness Month, a new analysis from Komodo Health, the leader in AI-powered healthcare intelligence, conducted in collaboration with the Tigerlily Foundation, a national breast cancer patient advocacy organization, delivers critical insights into antibody-drug conjugate (ADC) treatment patterns in metastatic breast cancer. The study confirms growing clinical acceptance of this innovative therapy but also reveal...

Breakthrough Alzheimer’s Therapies Drive Early Detection Rates While Exposing Deep Treatment Disparities

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--New research from Komodo Health and Medscape Education reveals both progress and persistent challenges in Alzheimer's disease care: Breakthrough therapies and targeted medical education are driving significant increases in early detection — with cognitive screening rising 10%, biomarker testing up 23%, and amyloid pathology testing surging more than 13-fold. However, patients at the highest risk are receiving treatments at the lowest rates. The analysi...
Back to Newsroom